Ownership Submission
FORM 3
 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
  Nanda Nisha
 2. Date of Event Requiring Statement (Month/Day/Year)
01/02/2019		 3. Issuer Name and Ticker or Trading Symbol
Loxo Oncology, Inc. [LOXO]
(Last)
(First)
(Middle)
C/O LOXO ONCOLOGY, INC., 281 TRESSER BOULEVARD, 9TH FLOOR		 4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
Chief Development Officer
 5. If Amendment, Date Original Filed(Month/Day/Year)
(Street)

STAMFORD, CT 06901		 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)		 2. Amount of Securities Beneficially Owned
(Instr. 4)		 3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)		 4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock 18,896
D
 

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4)		 2. Date Exercisable and Expiration Date
(Month/Day/Year)		 3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)		 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)		 6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Employee Stock Option (Right to Buy)   (1) 03/03/2024 Common Stock 16,983 $ 1.184 D  
Employee Stock Option (Right to Buy)   (1) 03/03/2024 Common Stock 14,828 $ 1.184 D  
Employee Stock Option (Right to Buy)   (1) 06/18/2024 Common Stock 4,557 $ 3.648 D  
Employee Stock Option (Right to Buy)   (1) 12/18/2024 Common Stock 10,861 $ 13.67 D  
Employee Stock Option (Right to Buy)   (2) 12/15/2025 Common Stock 9,228 $ 31.69 D  
Employee Stock Option (Right to Buy)   (3) 09/14/2026 Common Stock 14,870 $ 27 D  
Employee Stock Option (Right to Buy)   (4) 12/05/2026 Common Stock 18,375 $ 26.27 D  
Employee Stock Option (Right to Buy)   (5) 03/14/2027 Common Stock 12,000 $ 43.56 D  
Employee Stock Option (Right to Buy)   (6) 01/03/2028 Common Stock 75,000 $ 84.88 D  

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Nanda Nisha
C/O LOXO ONCOLOGY, INC.
281 TRESSER BOULEVARD, 9TH FLOOR
STAMFORD, CT 06901		       Chief Development Officer  

Signatures

/s/Jennifer Burstein, by power of attorney 01/02/2019
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) The stock option is fully vested and exercisable.
(2) The stock option vests and becomes exercisable as to 1/48th of the total number of shares on January 16, 2016, then an additional 1/48th vests on each monthly anniversary thereafter, until such time as the option is 100% vested, subject to the reporting person's continued service through each vesting date.
(3) The stock option vests and becomes exercisable as to 1/48th of the total number of shares on October 15, 2016, then an additional 1/48th vests on each monthly anniversary thereafter, until such time as the option is 100% vested, subject to the reporting person's continued service through each vesting date.
(4) The stock option vests and becomes exercisable as to 1/48th of the total number of shares on January 6, 2017, then an additional 1/48th vests on each monthly anniversary thereafter, until such time as the option is 100% vested, subject to the reporting person's continued service through each vesting date.
(5) The stock option vests and becomes exercisable as to 1/48th of the total number of shares on April 15, 2017, then an additional 1/48th vests on each monthly anniversary thereafter, until such time as the option is 100% vested, subject to the reporting person's continued service through each vesting date.
(6) The stock option vests and becomes exercisable as to 1/24th of the total number of shares on March 4, 2018, then an additional 1/48th vests on each monthly anniversary thereafter, until such time as the option is 100% vested, subject to the reporting person's continued service through each vesting date.
 
Remarks:
Exhibit List - Exhibit 24.1 - Power of Attorney

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.